Jan 16, 2020 / 05:30PM GMT
Matthew Thomas Holt - JP Morgan Chase & Co, Research Division - Analyst
Good morning, everyone, and welcome to the last day of the JPMorgan Healthcare Conference. My name is Matthew Holt, and I'm part of the equity research biotech team here at JPMorgan.
It's my pleasure to introduce our next presenting company, Acorda Therapeutics. Presenting today for Acorda will be President and CEO, Ron Cohen. And please note that following today's presentation, there will be a breakout session across the hall in the Georgian Room.
So with that, I hand it over to Ron.
Ron Cohen - Acorda Therapeutics, Inc. - Founder, CEO, President & Director
Thanks, Matthew, and thanks to JPMorgan for having us. Thank you all for being here. Good morning.
I'm going to take you through a review of a quarter over the last year and moving forward. Before I start, a reminder that the presentation will contain forward-looking statements, and we encourage you to consult our filings in more detail with the SEC.
First, for those of you who may not be
Acorda Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot